Clinical Trial Update: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating REGN4461, a leptin receptor agonist antibody, for familial partial lipodystrophy was terminated with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Partial Lipodystrophy

Drugs mentioned

• REGN4461

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Familial Partial Lipodystrophy, Metabolic Abnormalities | Phase 2 | Status: TERMINATED | Results posted: 2025-07-02